Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
Yao, Chih-Chien
Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. [electronic resource] - Journal of gastroenterology and hepatology May 2015 - 918-24 p. digital
Publication Type: Journal Article
1440-1746
10.1111/jgh.12874 doi
Adult
Aging--immunology
Antiviral Agents--therapeutic use
Consolidation Chemotherapy
Female
Follow-Up Studies
Forecasting
Hepatitis B--drug therapy
Hepatitis B e Antigens--blood
Humans
Lamivudine--therapeutic use
Male
Middle Aged
Molecular Sequence Data
Nucleotides--immunology
Recurrence
Retrospective Studies
Risk
Seroconversion
Time Factors
Young Adult
Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. [electronic resource] - Journal of gastroenterology and hepatology May 2015 - 918-24 p. digital
Publication Type: Journal Article
1440-1746
10.1111/jgh.12874 doi
Adult
Aging--immunology
Antiviral Agents--therapeutic use
Consolidation Chemotherapy
Female
Follow-Up Studies
Forecasting
Hepatitis B--drug therapy
Hepatitis B e Antigens--blood
Humans
Lamivudine--therapeutic use
Male
Middle Aged
Molecular Sequence Data
Nucleotides--immunology
Recurrence
Retrospective Studies
Risk
Seroconversion
Time Factors
Young Adult